Efficacy of icotinib in advanced lung squamous cell carcinoma
Author:
Affiliation:
1. Division of Respiratory MedicinePeking Union Medical College HospitalPeking Union Medical CollegeChinese Academy of Medical Sciences Beijing China
2. Zhejiang Betta Pharmaceuticals Hangzhou China
Publisher
Wiley
Subject
Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.1736
Reference42 articles.
1. Cancer statistics, 2017
2. Lung Cancer: Epidemiology, Etiology, and Prevention
3. Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
4. First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
5. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Elevated of HSP90 associates with expression of EGFR levels and predicts poor prognosis in non-small cell lung cancer patients;2022-10-07
2. Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials;Signal Transduction and Targeted Therapy;2022-10-05
3. Tissue Rigidity Increased during Carcinogenesis of NTCU-Induced Lung Squamous Cell Carcinoma In Vivo;Biomedicines;2022-09-23
4. Quinazoline‐Assisted ortho ‐Halogenation with N ‐Halosuccinimides through Pd(II)‐Catalyzed C(sp 2 )−H Activation;European Journal of Organic Chemistry;2022-04-29
5. Clinical outcomes of EGFR-TKIs in advanced squamous cell lung cancer;Neoplasma;2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3